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Marginal zone B-cell lymphomas (MZL) are classically characterized by an indolent proliferation of CD5 À , CD23 À , CD43 À , CCND1 À and CD10 À B cells that strongly express CD19, CD20, CD22, IgM and IgD, even if CD5 þ cases have been characterized. 1 The World Health Organization (WHO) 2 classifies marginal B-cell lymphomas into splenic marginal zone lymphoma (SMZL), nodal MZL and extranodal MZL of mucosa-associated lymphoid tissue (MALT). 2 Among the lymphomas developed from the spleen, the splenic diffuse red pulp lymphoma with villous lymphocytes (SDRPLs) has been described as provisional entity close to but distinct from SMZL. 2, 3 For small to intermediate-sized circulating abnormal lymphocytes, MZL diagnosis can be of great difficulty, particularly because there is no immunological-positive marker to distinguish MZL from atypical chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and lymphoplasmacytic lymphoma (LPL). Moreover, if translocations involving MALT1 (t(11;18), t(14;18)), BCL10 (t(1;14)) or FOXP1 (t(3;14)) are primarily associated with MALT, and del7q is frequent in SMZL, these cytogenetic markers are not always present. Therefore, there is no specific immunologic marker for splenic or nodal MZL.
To improve the diagnosis of chronic B-cell lymphoproliferative disease (B-LPD) with circulating cells, we have previously developed an innovative mass spectrometry-based proteomic workflow on plasma membrane microparticles derived from B-LPD 4 and proposed CD148 as a potential marker for MCL diagnosis panel. 5 Using again the proteomic toolbox, a differential proteomic analysis was applied here to compare the membrane proteomes originating from MPs derived from the following three different B-LPD: LPL, MCL and MZL.
A list of 388 unique membrane proteins was obtained including 59 CD annotated cell-surface proteins (Supplementary Table) . Within this list of characterized cell-surface proteins, we focused on CD180, also called Radio-Protective 105 (RP105) or lymphocyte antigen 64, which was considered overexpressed in the MZL sample by our semi-quantitative mass spectrometry analysis (peptide and spectral counting). CD180 is a leucine-rich repeat type 1 membrane protein belonging to the Toll-like receptor (TLR) family, with significant extracellular homology to the lipopolysaccharide receptor. 6 Its expression is restricted to antigen presenting cells, such as B cells, monocytes, macrophages and dendritic cells, and anti-CD180 antibodies activate the majority of human and mouse B cells in vitro. 7, 8 The literature describes opposite functions for CD180; however, it has been shown that CD180 ligation induces significant B-cell proliferation and Ig production, in both humans and mice. 7, 8 CD180 expression in B-CLL has been previously described to be different from that in normal CD19 þ blood cells. 9 In this paper, we evaluated CD180 expression using flow cytometry in two independent series of B-LPD patients from two French hematology departments, including 60 cases of MZL that were centrally reviewed.
Ninety-six blood samples from patients referred for investigation or follow-up of B-LPD in the Oncology and Hematology Department of the Strasbourg University Hospital were tested: 30 patients with CLL, 16 patients with MCL, 15 patients with LPL and 35 patients with MZL (25 splenic, 10 nodal without splenomegaly), in addition to 25 controls. Blood cells samples were collected after signed informed consent was obtained (Comité de protection des personnes EST-IV, # AC-2008-438) in accordance with the Declaration of Helsinki, and the Ethic Committee of the Faculty of Medicine of Strasbourg approved the study in 2011. Over 93% of the patients were included in the study at the time of diagnosis, and all patients presented a low count of circulating residual normal B cells. All cases of MCL displayed a t(11;14) and/or cyclin D1 hyperexpression. All cases of CLL had a Matutes score of 4 or 5. Only cases of MZL without plasma differentiation were selected in this study. Nine patients with SMZL displayed circulating villous lymphocytes.
As previously described, normal B cells displayed strong staining for CD180. CD27 þ and CD27 À cells were equally stained and only a small percentage of CD180 À B cells were observed in the controls (mean 5.3%, range 0.4-14%, data not shown). In agreement with previous studies 9 malignant B cells of CLL displayed weaker expression of CD180 (Po0.0001 MannWhitney U-test) (Figure 1b) .
We observed that CD180 staining was also weak in MCL (Po0.001) and LPL (Po0.001) B cells (Figures 1a and b) . did not differ significantly (P40.05, one-way analysis of variance (ANOVA)) and were all significantly lower than the controls (Po0.001, one-way ANOVA and Figure 1b) .
By contrast, as hypothesized from the mass spectrometry studies, circulating MZL cells had a high CD180 MFI, which was not different from the controls (P40.05) but was significantly higher than the CLL, MCL and LPL B cells (Po0.001, non-parametric oneway ANOVA). CD180 staining appeared more heterogeneous in the MZL cells than the control B cells (mean 5865
Similar results were obtained using a second anti-CD180 clone that was used to stain approximately one-third of the patients and control cells (clone MHR73-11, eBiosciences, San Diego, CA, USA; data not shown).
In the same way, the CD180 expression was performed in an independent series of 123 consecutive and prospective peripheral blood samples from patients with B-LPD diagnosed in the Hematology Department of Lyon-Sud University Hospital, according to 2008 WHO recommendations and after integration of all data (cytology, histology, flow cytometry immunophenotyping, conventional and molecular cytogenetics). These cases were classified as CLL (n ¼ 80), MZL (n ¼ 25), MCL (n ¼ 10) and SDRPL (n ¼ 8).
The MZL cases presented a strong CD180 expression (median ¼ 537), whereas the MCL and CLL cases showed a very dim or negative CD180 expression (median ¼ 126 and median ¼ 171, respectively) ( Figure 1c) . The difference of CD180 MFI values between Strasbourg and Lyon could be explained by lack of standardization between both cytometers. In both centers CLL and MCL B cells displayed a low CD180 staining, always weaker than in those of MZL, whatever their mutational status.
To confirm the flow cytometric protein expression data, total RNA was extracted from highly purified B cells. CD180 RQ-PCR was performed on CD19 þ and CD19 À fractions of separated blood lymphocytes of 10 CLL, 6 MZL and 6 MCL patient samples, and 5 normal control individuals. As expected, the CD180 transcript was Abbreviations: CLL, chronic lymphocytic leukemia; LPL, lymphoplasmacytic lymphoma; MCL, mantle cell lymphoma; MFI, mean fluorescence intensity; MZL, marginal zone lymphoma; RFI, relative fluorescence intensity (over negative controls); SMZL, splenic MZL; SDRPL, splenic diffuse red pulp B-cell lymphoma with villous lymphocytes. Median, (range) and s.d. of CD180 expression. CD180 immunolabelling was performed with the phycoerythrin-conjugated RP105 (clone G28.8, BD Biosciences, Franklin Lakes, NJ, USA) and CD19 (clone 5J25C1, Per-CP, BD Biosciences) using standard procedures. An IgG1 isotype control was also tested for each patient, and the whole blood samples were analyzed within 24 h. detected in normal B cells. It was very weakly detected in the CD19 À lymphocyte fraction, which primarily contains T cells that do not express CD180 at their surface. The CD180 transcript was also detected in all B-LPD tested, and was expressed at variable but comparable levels to the CD19 þ lymphocytes of normal controls. Accordingly, CD180 expression was also observed in 56 samples of normal CD19 þ B cells and B-CLP using microarray analyses (public NCI GEO dataset GSE6691 10 ). To test whether variant transcripts may explain the lower expression of CD180 at the cell surface, RT-PCR products covering the entire transcript were sequenced in four CLL and three MZL-purified CD19 þ cells. According to whole genome sequencing studies of B-LPD, 11, 12 no somatic mutations to the coding sequence that was published previously (Genbank NM_005582.2) were observed. Only the rs169714 polymorphism (667A4G, Ile223Val) was detected in both CLL and MZL samples (data not shown). These results suggest that the lower expression of CD180 in CLL is not associated with the presence of an abnormal transcript.
To test the intracytoplasmic localization of the CD180 protein in B-LPD, FITC-and a PE-conjugated anti-CD180 antibodies were used alternatively for membrane and intracellular staining in CLL (n ¼ 5), MCL (n ¼ 5), MZL (n ¼ 5) and control blood samples (n ¼ 5). The two combinations revealed comparable intracytoplasmic staining of CD180 in all samples tested, which was not observed in control T cells, whereas the surface staining remained unchanged (data not shown). These findings suggest that the CD180 transcript and protein are present in normal and malignant B cells at similar levels. The area under the curve and receiver operating characteristic curve analysis were used to verify the accuracy of CD180 expression in MZL vs the other B-LPD (Supplementary Figure 1) . It appeared that the CD180 MFI or RFI could positively discriminate MZL from CLL, LPL and MCL with more than 86% sensitivity and specificity. These results were obtained in two independent sets of patients, tested in two different laboratories.
To the best of our knowledge, no other available positive marker can be used for this type of characterization. Also, a high CD180 staining may be in favor of a splenic origin of the lymphoma, as SMZL and SDRPL display particularly high levels of CD180 expression. These results require however further confirmation in a larger cooperative study to assess its diagnostic potential.
In conclusion, this study shows the differential expression of CD180 in circulating cells of B-LPD, with high expression restricted to MZL and SDRPL B cells.
